Modified polynucleotides for reducing off-target effects in RNA interference
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
C07H-021/00
출원번호
UP-0019831
(2004-12-22)
등록번호
US-7595387
(2009-10-12)
발명자
/ 주소
Leake, Devin
Reynolds, Angela
Khvorova, Anastasia
Marshall, William
Linsley, Peter S.
출원인 / 주소
Dharmacon, Inc.
Merck & Co., Inc.
대리인 / 주소
Kalow & Springut, LLP
인용정보
피인용 횟수 :
83인용 특허 :
174
초록▼
Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Un
Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2'-O-alkyl or mismatch modification(s) at specific positions on the sense and/or antisense strands.
대표청구항▼
What is claimed is: 1. A double stranded polyribonucleotide comprising: a. a sense strand comprising a sense region, wherein said sense region comprises: i. a first 5' sense nucleotide, wherein said first 5' sense nucleotide comprises a first 2'-O-alkyl modification, and ii. a second 5' sense nucle
What is claimed is: 1. A double stranded polyribonucleotide comprising: a. a sense strand comprising a sense region, wherein said sense region comprises: i. a first 5' sense nucleotide, wherein said first 5' sense nucleotide comprises a first 2'-O-alkyl modification, and ii. a second 5' sense nucleotide, wherein said second 5' sense nucleotide comprises a second 2'-O-alkyl modification; and b. an antisense strand comprising an antisense region, wherein said antisense region comprises: i. a first 5' antisense nucleotide, wherein said first 5' antisense nucleotide is phosphorylated, and ii. a second 5' antisense nucleotide, wherein said second 5' antisense nucleotide comprises a third 2'-O-alkyl modification, wherein said sense region and said antisense region are capable of forming a duplex of 18-24 base pairs of nucleotides that has at least 80% complementarity over the range of the duplex, and within said duplex said first 5' sense nucleotide is the 5' most nucleotide of the sense strand, said second 5' sense nucleotide is immediately adjacent to and downstream of the first 5' sense nucleotide, said first 5' antisense nucleotide is the 5' most nucleotide of the antisense strand and said second 5' antisense nucleotide is immediately adjacent to and downstream of the first 5' antisense nucleotide, wherein all nucleotides of each strand of said double stranded polyribonucleotide other than said first 5' sense nucleotide, said second 5' sense nucleotide, and said second 5' antisense nucleotide comprises a 2'-OH, and wherein said antisense strand is capable of silencing a target gene with reduced off-target gene silencing. 2. The double stranded polyribonucleotide of claim 1, wherein said first 2'-O-alkyl modification comprises 2'-O-methyl, said second 2'-O-alkyl modification comprises 2'-O-methyl, and said third 2'-O-alkyl modification comprises 2'-O-methyl. 3. The double stranded polyribonucleotide of claim 1, wherein the double stranded polyribonucleotide comprises a 3' overhang, and said 3' overhang is 1 to 6 bases on at least one of said sense strand or said antisense strand. 4. The double stranded polyribonucleotide of claim 1, wherein said first 2'-O-alkyl modification, second 2'-O-alkyl modification, and third 2'-O-alkyl modification are independently selected from the group consisting of 2'-O-ethyl, 2'-O-propyl, 2'-O-isopropyl, 2'-O-butyl, 2'-O-isobutyl, 2'-O-ethyl-O-methyl, and 2'-O-ethyl-OH. 5. The double stranded polyribonucleotide of claim 1, wherein only said first 5' antisense nucleotide is phosphorylated. 6. The double stranded polyribonucleotide of claim 3, wherein said 3' overhang is 2 bases on at least one of said sense strand or said antisense strand. 7. The double stranded polyribonucleotide of claim 1, wherein said double stranded polyribonucleotide has reduced off-target gene silencing activity compared to a double stranded polyribonucleotide having the same nucleotide sequence as said double stranded polyribonucleotide, but does not contain 2'-O-alkyl modifications in said sense and antisense strands. 8. The double stranded polyribonucleotide of claim 1, wherein said double stranded polyribonucleotide has reduced off-target gene silencing activity compared to a double stranded polyribonucleotide having the same nucleotide sequence as said double stranded polyribonucleotide, but does not contain 2'-O-alkyl modifications in said antisense strand. 9. A double stranded polyribonucleotide comprising: a. a sense strand comprising a sense region, wherein said sense region comprises: i. a first 5' sense nucleotide, wherein said first 5' sense nucleotide comprises a first 2'-O-methyl modification, and ii. a second 5' sense nucleotide, wherein said second 5' sense nucleotide comprises a second 2'-O-methyl modification; and b. an antisense strand comprising an antisense region, wherein said antisense region comprises: i. a first 5' antisense nucleotide, wherein said first 5' antisense nucleotide is phosphorylated, and ii. a second 5' antisense nucleotide, wherein said second 5' antisense nucleotide comprises a third 2'-O-methyl modification, wherein said sense region and said antisense region are capable of forming a duplex of 19 base pairs of nucleotides that has at least 80% complementarity over the range of the duplex, and within said duplex said first 5' sense nucleotide is the 5' most nucleotide of the sense strand, said second 5' sense nucleotide is immediately adjacent to and downstream of the first 5' sense nucleotide, said first 5' antisense nucleotide is the 5' most nucleotide of the antisense strand and said second 5' antisense nucleotide is immediately adjacent to and downstream of the first 5' antisense nucleotide, wherein all nucleotides of each strand of said double stranded polyribonucleotide other than said first 5' sense nucleotide, said second 5' sense nucleotide, and said second 5' antisense nucleotide comprises a 2'-OH, wherein the double stranded polyribonucleotide comprises an overhang of two nucleotides at the 3' termini of both said sense strand and said antisense strand and wherein said antisense strand is capable of silencing a target gene with reduced off-target gene silencing. 10. The double stranded polyribonucleotide of claim 9, wherein said duplex of 19 base pairs of nucleotides has 100% complementarity over the range of the duplex and the two nucleotides of said overhangs at the 3' termini of the sense strand and the antisense strand are UU.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (174)
Buhr Chris A. ; Matteucci Mark, 2' Modified Oligonucleotides.
Brian C. Froehler ; Arnold J. Gutierrez ; Mark D. Matteucci, 2-Aminopyridine and 2-pyridone C-nucleosides, oligonucleotides comprising, and tests using the same oligonucleotides.
Fraser Allister S. ; Manoharan Muthiah ; Cook Phillip Dan ; Jung Michael E. ; Kawasaki Andrew M., Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates.
David J. Ecker ; Phillip Dan Cook ; Brett P. Monia ; Susan M. Freier ; Yogesh S. Sanghvi, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
Ecker David J. ; Cook Phillip Dan ; Monia Brett P. ; Freier Susan M. ; Sanghvi Yogesh S., Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
Brenda F. Baker ; Lex M. Cowsert ; Brett P. Monia ; Xaoxing S. Xu, Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs).
McKay, Robert; Dean, Nicholas M.; Monia, Brett P.; Nero, Pamela; Gaarde, William A., Antisense oligonucleotide compositions and methods for the modulation of JNK proteins.
Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
Gonye, Gregory E.; Hanafey, Michael K.; LaRossa, Robert A.; Rafalski, J. Antoni; Van Dyk, Tina K., Cellular arrays for the identification of altered gene expression.
Cook Phillip D. (Carlsbad CA) Bruice Thomas (Carlsbad CA) Guinosso Charles J. (Carlsbad CA) Kawasaki Andrew M. (Oceanside CA), Compositions for inhibiting RNA activity.
Walder Joseph A. ; Walder Roxanne Y. ; Eder Paul S. ; Dagle John M., DNA molecules stabilized by modifications of the 3'-terminal phosphodiester linkage.
Li Li-Chun ; Liu Lawrence C. ; Murray Michael A., DRAM with edge sense amplifiers which are activated along with sense amplifiers internal to the array during a read cycl.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Brian Froehler ; Rick Wagner ; Mark Mattencci ; Robert J. Jones ; Arnold J. Gutierrez ; Jeff Pudlo, Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Peter C. Roberts ; Bruce L. Frank ; David E. Szymkowski ; John S. Mills GB; John Goodchild ; Jia L. Wolfe ; Robert E. Kilkuskie ; Isobel M. Greenfield GB; Veronica Sullivan GB, HPV-specific oligonucleotides.
Agrawal Sudhir (46G Brandywine Dr. Shrewsbury MA 01545) Leiter Josef M. E. (111 Hicks St. ; #25C Brooklyn NY 11201) Palese Peter (414 Highwood Ave. Leonia NJ 07605) Zamecnik Paul C. (29 LeBeaux Dr. S, Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Dunlay, R. Terry; Taylor, D. Lansing; Gough, Albert H.; Giuliano, Kenneth A., Machine readable storage media for detecting distribution of macromolecules between nucleus and cytoplasm in cells.
Stec Wojciech J. (Lodz PLX) Uznanski Bogdan (Lodz CA PLX) Bergot B. John (Redwood City CA) Hirschbein Bernard L. (San Francisco CA) Fearon Karen L. (Union City CA), Method of synethesizing sulfurized oligonucleotide analogs.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Manns Roy L. (Marshfield Hills MA) Kolb Alfred J. (Madison CT) Effertz Bernard S. (Meriden CT), Microplate forming wells with transparent bottom walls for assays using light measurements.
Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
Hanecak,Ronnie C.; Anderson,Kevin P.; Bennett,C. Frank; Chiang,Ming Yi; Brown Driver,Vickie L.; Ecker,David J.; Vickers,Timothy A.; Wyatt,Jacqueline R., Modulation of telomere length by oligonucleotides having a G-core sequence.
Lin Kuei-Ying (Fremont CA) Matteucci Mark (Burlingame CA), Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Cook Phillip Dan ; Sanghvi Yogesh S. ; Sprankle Kelly G. ; Ross Bruce S. ; Griffey Rich H., Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions.
Cook Phillip Dan ; Sanghvi Yogesh S. ; Sprankle Kelly G. ; Ross Bruce S. ; Griffey Rich H. ; Springer Robert H., Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom.
Anuschirwan Peyman DE; Eugen Uhlmann DE; Matthias Mag DE; Gerhard Kretzschmar DE; Matthias Helsberg DE; Irvin Winkler DE, Stabilized oligonucleotides and their use.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
Brown, David; Ford, Lance P.; Jarvis, Richard A.; Pallotta, Vince; Pasloske, Brittan L., High potency siRNAS for reducing the expression of target genes.
Zamore, Phillip D.; Hutvagner, Gyorgy; Schwarz, Dianne; Simard, Martin, Methods and compositions for enhancing the efficacy and specificity of RNA silencing.
Zamore, Phillip D.; Hutvagner, Gyorgy; Schwarz, Dianne; Simard, Martin, Methods and compositions for enhancing the efficacy and specificity of RNA silencing.
Zamore, Phillip D.; Hutvagner, Gyorgy; Schwarz, Dianne; Simard, Martin, Methods and compositions for enhancing the efficacy and specificity of RNA silencing.
Zamore, Phillip D.; Hutvagner, Gyorgy; Schwarz, Dianne; Simard, Martin, Methods and compositions for enhancing the efficacy and specificity of RNA silencing.
Woolf, Tod M.; Kamens, Joanne; Salomon, William; Khvorova, Anastasia, RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.